FDA extends PDUFA for CompleoTRT

Trimel Pharmaceuticals Corp. (TSX:TRL) fell C$0.21 (26%) to C$0.60 on Friday after FDA extended by three months the PDUFA date for an NDA for CompleoTRT to treat testosterone deficiency. The new PDUFA...